Advances in Inflammatory Bowel Diseases (AIBD 2018)

Joint pain common EIM in IBD

Audrey Abella, 20190129100000

Joint pain is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD), according to a presentation during AIBD 2018.

Post-marketing data reaaffirm vedolizumab safety in real world

Post-marketing data reaffirm vedolizumab safety in real world

Pearl Toh, 20190128190010

The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.

Low rate of C. difficile infection in UC patients on tofacitinib

Roshini Claire Anthony, 20190128140203

The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.

Paediatric-onset IBD tied to more severe disease course

Elaine Soliven, 20190125080035

Patients with paediatric-onset inflammatory bowel disease (pIBD) have a higher incidence of severe IBD than those with adult-onset IBD (aIBD), according to a study presented at AIBD 2018.

Older age a risk factor for AEs during ulcerative colitis treatment

Elaine Soliven, 20190123033029

Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.

High intra-, postoperative complication risks in patients with obesity and ulcerative colitis

Roshini Claire Anthony, 20190122140202

Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).

Ferric carboxymaltose preferred over other iron compounds for IDA in IBD

Audrey Abella, 20190122070726

Ferric carboxymaltose (FCM) remains the most effective intravenous (IV) iron formulation as monotherapy followed by iron sucrose/saccharate (IS) and presented a better safety profile with fewer adverse events (AEs) in patients with inflammatory bowel disease (IBD) with iron deficiency anaemia (IDA), according to an updated meta-analysis presented at AIBD 2018.

Vedolizumab a “new chapter” for IBD therapy beyond anti-TNF

Pearl Toh, 20190121190010

The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.

Do probiotics have a role in ulcerative colitis?

Pearl Toh, 20190118190010

While probiotics may help induce remission in patients with ulcerative colitis (UC), its role in remission maintenance is less certain, suggests two studies presented at AIBD 2018.